Iovance Biotherapeutics, Inc.IOVANASDAQ
Loading
SG&A Expenses Over TimeStrong
Percentile Rank93
3Y CAGR+13.5%
5Y CAGR+20.4%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+13.5%/yr
vs +38.3%/yr prior
5Y CAGR
+20.4%/yr
Recent deceleration
Acceleration
-24.8pp
Decelerating
Percentile
P93
Near historical high
vs 5Y Ago
2.5x
Strong expansion
Streak
1 yr
Consecutive declineStrong
PeriodValueYoY Change
TTM$152.32M-0.5%
2024$153.02M+43.1%
2023$106.92M+2.7%
2022$104.10M+24.4%
2021$83.66M+39.0%
2020$60.21M+47.4%
2019$40.85M+43.7%
2018$28.43M+33.7%
2017$21.26M+23.6%
2016$17.20M-